Cited 21 times in
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2014-12-20T16:55:59Z | - |
dc.date.available | 2014-12-20T16:55:59Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1340-6868 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93654 | - |
dc.description.abstract | BACKGROUND: The primary objective of this multicenter, open-label, randomized, parallel, phase II selection trial was to compare the objective tumor response to biweekly (every 2 weeks) gemcitabine/paclitaxel, gemcitabine/carboplatin, and gemcitabine/cisplatin as first-line treatment for metastatic breast cancer. PATIENTS AND METHODS: Eligible patients with stage IV disease who relapsed after anthracycline failure were randomly assigned in a 1:1:1 ratio to gemcitabine (2,500 mg/m2) plus paclitaxel 150 mg/m2 (n = 49); plus carboplatin, area under the curve = 2.5 mg/mL × min (n = 47); or plus cisplatin 50 mg/m2 (n = 51). Study therapy continued up until a maximum of 8 cycles and follow-up continued for 24 months. RESULTS: All patients were analyzed for efficacy and one patient was excluded from the safety analyses. The objective response was 26.5% [95% confidence interval (CI) 14.9-41.1] for gemcitabine/paclitaxel, 17.0% (95% CI 7.6-30.8) for gemcitabine/carboplatin, and 15.7% (95% CI 7.0-28.6) for gemcitabine/cisplatin. The adjusted odds ratio for tumor response was 0.33 (95% CI 0.10-1.06), P = 0.063 for gemcitabine/carboplatin versus gemcitabine/paclitaxel; 0.26 (95% CI 0.08-0.86), P = 0.027 for gemcitabine/cisplatin versus gemcitabine/paclitaxel; and 0.77 (95% CI 0.24-2.52), P = 0.671 for gemcitabine/cisplatin versus gemcitabine/carboplatin. There were no significant differences in overall survival or progression-free survival (P > 0.05). Grade 3 or 4 drug-related adverse events varied between groups and the majority of deaths (94.9%; 74/78) were related to disease progression. CONCLUSIONS: The gemcitabine-based treatments had comparable activity and tolerability. Similar survival characteristics and different toxicity profiles suggested that gemcitabine-platinum may be evaluated further in patients after anthracycline failure. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 203~212 | - |
dc.relation.isPartOf | BREAST CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Anthracyclines/administration & dosage | - |
dc.subject.MESH | Anthracyclines/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/mortality | - |
dc.subject.MESH | Breast Neoplasms/pathology* | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carboplatin/adverse effects | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/drug therapy* | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/pathology | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/adverse effects | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Paclitaxel/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Binghe Xu | - |
dc.contributor.googleauthor | Zefei Jiang | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Shiying Yu | - |
dc.contributor.googleauthor | Jifeng Feng | - |
dc.contributor.googleauthor | Artur Malzyner | - |
dc.contributor.googleauthor | Auro del Giglio | - |
dc.contributor.googleauthor | Hyun C. Chung | - |
dc.contributor.googleauthor | Li Jun Shen | - |
dc.contributor.googleauthor | Daniel Lee Kay Pen | - |
dc.identifier.doi | 10.1007/s12282-011-0260-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00401 | - |
dc.identifier.eissn | 1880-4233 | - |
dc.identifier.pmid | 21465229 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs12282-011-0260-y | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | Carboplatin | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Breast cancer | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 18 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 203 | - |
dc.citation.endPage | 212 | - |
dc.identifier.bibliographicCitation | BREAST CANCER, Vol.18(3) : 203-212, 2011 | - |
dc.identifier.rimsid | 28369 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.